Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.46 |
| ▸ | DDR2 | Q16832 | 3/20 | 0.46 |
| ▸ | MAPK11 | Q15759 | 3/20 | 0.46 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.46 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.46 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.44 |
| ▸ | SRC | P12931 | 2/20 | 0.43 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.42 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.42 |
| ▸ | ABL1 | P00519 | 1/20 | 0.42 |
| ▸ | ABL2 | P42684 | 1/20 | 0.42 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.42 |
| ▸ | KLKB1 | P03952 | 2/20 | 0.41 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.40 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.40 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.39 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 1/20 | 0.38 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3279042 | 0.90 | KDM4E (0.54) | MAPK14DDR2MAPK11MAPK13MAPK12 | |
| SCHEMBL3283975 | 0.84 | PTGS2 (0.54) | MAPK14MAPK11MAPK13MAPK12KDM4E | |
| SCHEMBL12859423 | 0.83 | PTGS1 (0.59) | KDM4EL3MBTL1PTGS1ALDH1A1PTGS2 | |
| SCHEMBL12859447 | 0.83 | TRPV1 (0.49) | — | |
| SCHEMBL12859491 | 0.77 | CNR1 (0.51) | MAPK14MAPK11MAPK13MAPK12KDM4E | |
| SCHEMBL3278428 | 0.76 | PTGS1 (0.76) | PTGS1PTGS2MAPTPDPK1TSHR | |
| SCHEMBL3284843 | 0.76 | PTGS1 (0.41) | KDM4EL3MBTL1PTGS1ALDH1A1PTGS2 | |
| SCHEMBL14198873 | 0.76 | TRPC3 (0.59) | MAPK14PTGS1PTGS2ALOX15TRPC3 | |
| SCHEMBL12859442 | 0.76 | PTGS2 (0.52) | PTGS1PTGS2TRPC3PDPK1 | |
| SCHEMBL14198877 | 0.75 | TRPC3 (0.51) | MAPK14MAPK11MAPK13MAPK12KDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7700655-B2 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2010-04-20 | — | — | US | disclosed |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2008-04-17 | — | — | US | disclosed |
| US-20070185059-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20070185110-A1 | Antiallergic agents | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2007-08-09 | — | — | US | disclosed |
| US-20060122243-A1 | Antiallergic | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-06-08 | — | — | US | disclosed |
| US-20060111409-A1 | Medicament for treatment of diabetes | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-25 | — | — | US | disclosed |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-05-11 | — | — | US | disclosed |
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | INSTITUTE OF MEDICINAL MOLECULAR DESIGN, INC. (JP) | 2006-01-26 | — | — | US | disclosed |
| EP-1514544-A1 | ANTIALLERGIC | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-16 | — | — | EP | disclosed |
| EP-1512396-A1 | INHIBITORS AGAINST THE ACTIVATION OF AP-1 AND NFAT | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-09 | — | — | EP | disclosed |
| EP-1510210-A1 | IMMUNITY-RELATED PROTEIN KINASE INHIBITORS | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
| EP-1510207-A1 | THERAPEUTIC DRUG FOR DIABETES | Institute of Medicinal Molecular Design, Inc. (JP) | 2005-03-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060019958-A1 | Immunity-related protein kinase inhibitors | MAP3K1, MAP3K7, MAP3K8 | MAPK14 85/4885DDR2 3747/4885MAPK11 214/4885 |
| US-20060111409-A1 | Medicament for treatment of diabetes | XDH, SLC5A1, SLC5A2 | MAPK14 1163/4885DDR2 4718/4885MAPK11 1874/4885 |
| US-20080090779-A1 | ANTIALLERGIC AGENTS | NAT1, EPX, HRH2 | MAPK14 2290/4885DDR2 4823/4885MAPK11 2141/4885 |
| US-20060122243-A1 | Antiallergic | EPX, NAT1, HNMT | MAPK14 2111/4885DDR2 4837/4885MAPK11 2116/4885 |
| US-20060100257-A1 | Inhibitors against the activation of ap-1 and nfat | NFATC1, AP1G1, ATF1 | MAPK14 523/4885DDR2 4680/4885MAPK11 787/4885 |
| US-20070185110-A1 | Antiallergic agents | NAT1, EPX, AHR | MAPK14 2398/4885DDR2 4813/4885MAPK11 2187/4885 |
| US-20070185059-A1 | Antiallergic agents | NAT1, EPX, AHR | MAPK14 2265/4885DDR2 4825/4885MAPK11 2054/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.